MUMBAI / MAHWAH, April 1, 2025 – Glenmark Pharmaceuticals Limited (BSE: 532296 | NSE: GLENMARK), through its U.S. subsidiary Glenmark Pharmaceuticals Inc., has announced the launch of Vancomycin Hydrochloride for Injection USP in strengths of 750 mg/vial, 1.25 g/vial, and 1.5 g/vial in the United States.
Product Launch Overview
The injectable antibiotic, presented in single-dose vials, is bioequivalent and therapeutically equivalent to the reference listed drug (RLD) marketed by Mylan Laboratories Limited under NDA 209481.According to IQVIA™ sales data for the 12-month period ending January 2025, the market for Vancomycin Hydrochloride for Injection (covering brand and all therapeutic equivalents) generated annual sales of approximately $39.3 million in the U.S.
Executive Commentary
About the Product
Vancomycin Hydrochloride is a critical injectable antibiotic used in the treatment of serious bacterial infections, including those caused by Gram-positive organisms. The launch strengthens Glenmark’s institutional product offerings in the U.S. market, supporting its expansion in hospital-administered drugs.Company Snapshot
Glenmark Pharmaceuticals is a research-led global pharmaceutical company with a strong footprint across Branded, Generics, and OTC segments. It maintains focus on key therapeutic areas: cardio-metabolic, respiratory, dermatology, and oncology.- Global Operations: Present in over 80 countries, with 11 world-class manufacturing facilities across four continents.
- Recognitions:
- Ranked among the Top 100 Biopharma Companies by Pharmaceutical Sales in 2023 (Scrip 100)
- Featured in the Top 50 Generics & Biosimilar Companies by Generics Bulletin (2024)
- Sustainability Leadership: One of only two Indian pharmaceutical firms with Science Based Target initiative (SBTi)-approved GHG emission reduction targets.
- CSR Impact: Positively impacted over 3.3 million lives through social interventions in the past decade.